BACKGROUND AND OBJECTIVE: Despite advances in the treatment of hypertension, control rates continue to be suboptimal in both Europe and the US. Strategies that improve hypertension control are therefore urgently needed. This study aimed to assess the relative efficacies of various antihypertensive drugs commonly used in France in reducing systolic and diastolic blood pressure (SBP and DBP) by using a meta-analytical approach. This update of a previously published meta-analytical approach extends the number of drugs evaluated from 13 to 19. METHODS: A total of 80 randomised, controlled trials published between 1973 and 2007 involving 10 818 patients were selected for inclusion in the meta-analytical approach. Data were examined for 19 drugs, and 16 drugs were included in the analysis: hydrochlorothiazide, indapamide sustained-release (SR), atenolol, amlodipine, lercanidipine, manidipine, enalapril, ramipril, trandolapril, candesartan cilexetil, irbesartan, losartan, olmesartan medoxomil, telmisartan, valsartan and aliskiren. Weighted average reductions in SBP and DBP over a period of 8-12 weeks were calculated for each drug from information on both the mean and the variability in BP reduction. No trials evaluating furosemide, spironolactone or cicletanine satisfied the inclusion criteria for this analysis. RESULTS: The average weighted reductions in SBP over 8-12 weeks were most marked with diuretics, and in particular indapamide SR 1.5 mg/day (mean change from baseline -22.2mm Hg), which reduced SBP to a greater extent than any of the other drugs evaluated (at any dosage considered). Average weighted reductions in DBP were generally similar with all classes of antihypertensives and ranged from -11.4mm Hg with the beta-adrenoceptor blocker atenolol and calcium channel antagonists to -10.3mm Hg with the angiotensin II type 1 receptor antagonists. CONCLUSION: This new analysis supports the results of the earlier investigation, in that indapamide SR 1.5 mg/day appeared to be the most effective drug for producing significant reductions in SBP within 8-12 weeks, which is an essential element in optimising cardiovascular prevention among hypertensive patients. The clinical application of these results should take into consideration all the limitations discussed in this analysis.
BACKGROUND AND OBJECTIVE: Despite advances in the treatment of hypertension, control rates continue to be suboptimal in both Europe and the US. Strategies that improve hypertension control are therefore urgently needed. This study aimed to assess the relative efficacies of various antihypertensive drugs commonly used in France in reducing systolic and diastolic blood pressure (SBP and DBP) by using a meta-analytical approach. This update of a previously published meta-analytical approach extends the number of drugs evaluated from 13 to 19. METHODS: A total of 80 randomised, controlled trials published between 1973 and 2007 involving 10 818 patients were selected for inclusion in the meta-analytical approach. Data were examined for 19 drugs, and 16 drugs were included in the analysis: hydrochlorothiazide, indapamide sustained-release (SR), atenolol, amlodipine, lercanidipine, manidipine, enalapril, ramipril, trandolapril, candesartancilexetil, irbesartan, losartan, olmesartan medoxomil, telmisartan, valsartan and aliskiren. Weighted average reductions in SBP and DBP over a period of 8-12 weeks were calculated for each drug from information on both the mean and the variability in BP reduction. No trials evaluating furosemide, spironolactone or cicletanine satisfied the inclusion criteria for this analysis. RESULTS: The average weighted reductions in SBP over 8-12 weeks were most marked with diuretics, and in particular indapamideSR 1.5 mg/day (mean change from baseline -22.2mm Hg), which reduced SBP to a greater extent than any of the other drugs evaluated (at any dosage considered). Average weighted reductions in DBP were generally similar with all classes of antihypertensives and ranged from -11.4mm Hg with the beta-adrenoceptor blocker atenolol and calcium channel antagonists to -10.3mm Hg with the angiotensin II type 1 receptor antagonists. CONCLUSION: This new analysis supports the results of the earlier investigation, in that indapamideSR 1.5 mg/day appeared to be the most effective drug for producing significant reductions in SBP within 8-12 weeks, which is an essential element in optimising cardiovascular prevention among hypertensivepatients. The clinical application of these results should take into consideration all the limitations discussed in this analysis.
Authors: D Guez; J M Mallion; J P Degaute; P L Malini; R Baldwin; D Rodriguez-Pujol; A de Cordoüe; S Barrandon; C Chastang; M Safar Journal: Arch Mal Coeur Vaiss Date: 1996-09
Authors: A J Manolis; E Grossman; B Jelakovic; A Jacovides; D C Bernhardi; W J Cabrera; L A Watanabe; J Barragan; N Matadamas; A Mendiola; K S Woo; J R Zhu; A D Mejia; T Bunt; T Dumortier; R D Smith Journal: Clin Ther Date: 2000-10 Impact factor: 3.393
Authors: Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Sheila K Reiss; Dennis Ross-Degnan; Fang Zhang; Stephen B Soumerai; Alan M Zaslavsky; J Frank Wharam Journal: Health Serv Res Date: 2011-03-17 Impact factor: 3.402
Authors: Chieh-Wen Chen; Terry B J Kuo; Pei-Chi Hsu; Jai-Yi Li; Kuan-Liang Kuo; Cheryl C H Yang Journal: Hypertens Res Date: 2022-04-22 Impact factor: 5.528
Authors: Troy Hai Kiat Puar; Yingjuan Mok; Roy Debajyoti; Joan Khoo; Choon How How; Alvin Kok Heong Ng Journal: Singapore Med J Date: 2016-05 Impact factor: 1.858
Authors: Shelby D Reed; Yanhong Li; Eugene Z Oddone; Alice M Neary; Melinda M Orr; Janet M Grubber; Felicia L Graham; Maren K Olsen; Laura P Svetkey; Rowena J Dolor; Benjamin J Powers; Martha B Adams; Hayden B Bosworth Journal: Am J Hypertens Date: 2009-11-19 Impact factor: 2.689
Authors: John D Sluyter; Alun D Hughes; Andrew Lowe; Kim H Parker; Carlos A Camargo; Bernhard Hametner; Siegfried Wassertheurer; Robert K R Scragg Journal: Int J Cardiol Date: 2016-06-15 Impact factor: 4.164